Stock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat

Stock Track

8小时前

Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.

The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.

These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1181983787"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181983787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181983787?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181983787","market":"sg","top_or_hot":-1,"title":"Stock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.</p><p>The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.</p><p>These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 6.31% in Night Session on Strong Vaccine Data and Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.</p><p>The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.</p><p>These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1181983787","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181983787","pubTimestamp":1778457828,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.The movement was fueled by encouraging...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股赛道|Moderna夜盘大涨6.31%疫苗数据强劲营收超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) experienced a significant surge of 6.31% during the night session, driven by multiple positive catalysts that boosted investor sentiment.The movement was fueled by encouraging Phase 1 clinical data for Moderna's mRNA-based hantavirus vaccine, which showed favorable tolerability and elicited robust antibody responses. Additionally, the company reported first-quarter revenue of $389 million, substantially exceeding the analyst consensus estimate of $228 million. Further support came from positive first-in-human data for its personalized mRNA cancer therapeutic vaccine EVM16 and an upward revision of the stock's target price by UBS.These developments highlight the continued potential of Moderna's mRNA platform across various therapeutic areas, contributing to the strong upward price movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}